Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

<< Previous
Bullboard Posts
Next >>
Post by prophetoffactzon May 09, 2023 2:22pm
102 Views
Post# 35439042

Symrise Q1 results:

Symrise Q1 results:

04/26/2023 Corporate | Financial

Quarterly Statement January-March 2023
— Sales growth of 12.8 % in reporting currency in the first quarter
— Group sales rise to € 1.2 billion
— Organic growth of 10.6 %
— Targets for 2023 and medium-term goals for 2025 confirmed

Symrise AG made a successful start into the new year, benefiting from continued high demand and broad positioning. In the first quarter, the Group increased sales in the reporting currency by 12.8 % to € 1,230.2 million (Q1 2022: € 1,090.6 million). The company also recorded substantial organic sales growth of 10.6 % (previous quarter 8.3 %). Both segments contributed to the positive development.

Dr. Heinz-Jrgen Bertram, CEO of Symrise AG: “Symrise was able to seamlessly continue last year's positive business development at the beginning of this year. Despite high inflation and continued volatility in our markets, we are optimistic about the rest of the year and expect robust demand. Our diversified portfolio and our broad international positioning will also help us realize our growth potential and create lasting value this year. We therefore also confirm our outlook. For the current fiscal year, we are aiming for organic sales growth of 5 % to 7 % and an EBITDA margin of around 20 %."

Scent & Care: High demand for cosmetic ingredients

Scent & Care, the business with fragrances, aroma molecules and cosmetic ingredients, generated sales of € 454.0 million and grew by 8.3 % compared with the previous year's quarter (Q1 2022: € 419.3 million). Sales grew organically by 4.2 %.

In the Fragrance division, the luxury segment continued to show especially strong momentum. The Fine Fragrances business unit in particular benefited from this, generating growth in the high double-digit percentage range compared to the first quarter of the previous year. Sales in Consumer Fragrances achieved single-digit growth. Especially hygiene and cleaning products enjoyed great demand.

In the Aroma Molecules division, the difficult market environment led to a declining sales. Increasing competitive pressure from Asia and high inventories held by customers led to lower sales volumes. The menthols and terpenes product groups suffered from lower demand versus last year.

Sales in the Cosmetic Ingredients division continued to develop strongly in the first quarter of the current year, with organic growth in the double-digit percentage range. The most important growth drivers were the EAME regions (Europe, Africa, Middle East) and Latin America. Application areas with active cosmetic ingredients grew strongly.

Portfolio effects from the acquisitions of the French companies Nroli and Romani contributed to the segment’s sales with a total of € 15 million.

Taste, Nutrition & Health: Significant growth in applications for pet food as well as for food and beverages

The Taste, Nutrition & Health segment, in which Symrise bundles activities relating to taste solutions for food and beverages, pet food and nutrition, increased its sales by 15.6 % to € 776.1 million (Q1 2022: € 671.3 million). Organic growth reached 14.6 %. All regions contributed to this positive result. Strong growth drivers were the Latin America and EAME regions (Europe, Africa, Middle East).

The Food & Beverage division, with its beverages and sweet and savory application areas, achieved high, in some cases double-digit growth rates. Here too, the highest growth was achieved in the Latin America and EAME regions.

The Pet Food division continued its high double-digit growth rates. The strongest momentum for growth came from the EAME (Europe, Africa, Middle East) and Asia/Pacific regions. Expansion of capacity in Brazil, Mexico and North America is progressing and creating the basis for further international expansion of the business.

The sales contribution from the acquisition of Wing Pet Food in China was € 10 million in total.

Symrise confirms growth and profitability targets

Despite the current volatile market environment resulting from the war in Ukraine and persistently high inflation rates in many countries, Symrise is well-positioned to continue its profitable growth path, especially by expanding capacity and increasing prices. The company has a robust business model, a diversified portfolio of applications and a broad regional presence and customer base.

Symrise confirms its long-term profitable growth course. The company continues to expect to grow faster than the relevant market and to increase sales by 5 % to 7 % annually (CAGR) until 2025, with an EBITDA margin in the range of 20 % to 23 %. Despite continued high raw material prices and high logistics and energy costs, Symrise is aiming for an EBITDA margin of around 20 % in the 2023 fiscal year.

Financial Information Q1 2023


<< Previous
Bullboard Posts
Next >>